Aspergillus Infections in Transplant Recipients

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2005 Jan 18

PMID 15653818

Citations 150

Authors

Nina Singh

David L Paterson

Affiliations

Soon will be listed here.

Abstract

Aspergillus infections are occurring with an increasing frequency in transplant recipients. Notable changes in the epidemiologic characteristics of this infection have occurred; these include a change in risk factors and later onset of infection. Management of invasive aspergillosis continues to be challenging, and the mortality rate, despite the use of newer antifungal agents, remains unacceptably high. Performing molecular studies to discern new targets for antifungal activity, identifying signaling pathways that may be amenable to immunologic interventions, assessing combination regimens of antifungal agents or combining antifungal agents with modulation of the host defense mechanisms, and devising diagnostic assays that can rapidly and reliably diagnose infections represent areas for future investigations that may lead to further improvement in outcomes.

Citing Articles

Follow-up of Surgical and Nonsurgical Patients With Pulmonary Aspergillosis: A Real-World Study.

Chen Z, Shang Y, Wasti B, Ou Y, Gong S, Xiang X Infect Drug Resist. 2025; 18:1059-1070.

PMID: 40008248 PMC: 11853054. DOI: 10.2147/IDR.S496765.

The Molecular Basis of the Intrinsic and Acquired Resistance to Azole Antifungals in .

Hosseini P, Keniya M, Sagatova A, Toepfer S, Muller C, Tyndall J J Fungi (Basel). 2024; 10(12).

PMID: 39728316 PMC: 11678245. DOI: 10.3390/jof10120820.

A review of pathogenic airborne fungi and bacteria: unveiling occurrence, sources, and profound human health implication.

Al-Shaarani A, Pecoraro L Front Microbiol. 2024; 15:1428415.

PMID: 39364169 PMC: 11446796. DOI: 10.3389/fmicb.2024.1428415.

Vaccination with O-linked Mannans Protects against Systemic Candidiasis through Innate Lymphocyte Populations.

Taira C, Dos Santos Dias L, Lichtenberger S, Whitehead A, Kischkel B, Netea M J Immunol. 2024; 213(6):843-852.

PMID: 39109925 PMC: 11426167. DOI: 10.4049/jimmunol.2400065.

Renal Aspergillosis Complicating Renal Allograft Transplantation: A Case Report.

Malde S, Gupta S, Kashiv P, Sejpal K, Pasari A, Balwani M Cureus. 2024; 16(6):e61817.

PMID: 38975536 PMC: 11227294. DOI: 10.7759/cureus.61817.

References

Petraitiene R, Petraitis V, Groll A, Sein T, Piscitelli S, Candelario M . Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother. 2001; 45(3):857-69. PMC: 90385. DOI: 10.1128/AAC.45.3.857-869.2001. View

Ahlin A, Elinder G, Palmblad J . Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. Blood. 1997; 89(9):3396-401. View

Roilides E, Dimitriadou A, Kadiltsoglou I, Sein T, KARPOUZAS J, Pizzo P . IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Immunol. 1997; 158(1):322-9. View

Petrosillo N, Pellicelli A, Cicalini S, Conte A, Goletti D, Palmieri F . Endocarditis caused by Aspergillus species in injection drug users. Clin Infect Dis. 2001; 33(8):e97-9. DOI: 10.1086/323564. View

Torre-Cisneros J, Lopez O, Kusne S, Martinez A, Starzl T, Simmons R . CNS aspergillosis in organ transplantation: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1993; 56(2):188-93. PMC: 1014820. DOI: 10.1136/jnnp.56.2.188. View

Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, Alcazar-Fuoli L, Mellado E, Buitrago M . Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2005; 49(3):1232-5. PMC: 549263. DOI: 10.1128/AAC.49.3.1232-1235.2005. View

Arikan S, Paetznick V, Rex J . In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2001; 46(1):245-7. PMC: 127002. DOI: 10.1128/AAC.46.1.245-247.2002. View

Petraitis V, Petraitiene R, Sarafandi A, Kelaher A, Lyman C, Casler H . Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003; 187(12):1834-43. DOI: 10.1086/375420. View

Moosa M, Alangaden G, Manavathu E, Chandrasekar P . Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis. J Antimicrob Chemother. 2001; 49(1):209-13. DOI: 10.1093/jac/49.1.209. View

10.

Kusne S, Torre-Cisneros J, Manez R, Irish W, Martin M, Fung J . Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis. 1992; 166(6):1379-83. PMC: 3022485. DOI: 10.1093/infdis/166.6.1379. View

11.

Husain S, Alexander B, Munoz P, Avery R, Houston S, Pruett T . Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis. 2003; 37(2):221-9. DOI: 10.1086/375822. View

12.

Romero A, Le Pogamp P, Nilsson L, Wood N . Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther. 2002; 71(4):226-34. DOI: 10.1067/mcp.2002.121911. View

13.

Marr K, Crippa F, Leisenring W, Hoyle M, Boeckh M, Arunmozhi Balajee S . Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2003; 103(4):1527-33. DOI: 10.1182/blood-2003-08-2644. View

14.

Mennink-Kersten M, Klont R, Warris A, Op den Camp H, Verweij P . Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection. Lancet. 2004; 363(9405):325-7. DOI: 10.1016/S0140-6736(03)15393-7. View

15.

Conneally E, Cafferkey M, Daly P, Keane C, McCann S . Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant. 1990; 5(6):403-6. View

16.

Morrison V, Haake R, Weisdorf D . Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med. 1994; 96(6):497-503. DOI: 10.1016/0002-9343(94)90088-4. View

17.

Schmitt H . New methods of delivery of amphotericin B. Clin Infect Dis. 1993; 17 Suppl 2:S501-6. DOI: 10.1093/clinids/17.supplement_2.s501. View

18.

Calvo V, Borro J, Morales P, Morcillo A, Vicente R, Tarrazona V . Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest. 1999; 115(5):1301-4. DOI: 10.1378/chest.115.5.1301. View

19.

Goodman D, Pamer E, Jakubowski A, Morris C, Sepkowitz K . Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis. 2002; 35(3):E35-6. DOI: 10.1086/341305. View

20.

Rogers J, Rohal S, Carrigan D, Kusne S, Knox K, Gayowski T . Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation. 2000; 69(12):2566-73. DOI: 10.1097/00007890-200006270-00016. View